Log in

Microbot Medical Stock Price, Forecast & Analysis (NASDAQ:MBOT)

$4.80
-0.01 (-0.21 %)
(As of 11/19/2019 08:56 AM ET)
Today's Range
$4.68
Now: $4.80
$5.00
50-Day Range
$4.64
MA: $5.17
$5.91
52-Week Range
$1.38
Now: $4.80
$19.40
Volume29,100 shs
Average Volume34,610 shs
Market Capitalization$20.69 million
P/E RatioN/A
Dividend YieldN/A
Beta5
Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MBOT
CUSIPN/A
Phone781-875-3605

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.40 per share

Profitability

Net Income$-7,240,000.00

Miscellaneous

Employees9
Market Cap$20.69 million
Next Earnings Date11/20/2019 (Estimated)
OptionableNot Optionable

Receive MBOT News and Ratings via Email

Sign-up to receive the latest news and ratings for MBOT and its competitors with MarketBeat's FREE daily newsletter.


Microbot Medical (NASDAQ:MBOT) Frequently Asked Questions

What is Microbot Medical's stock symbol?

Microbot Medical trades on the NASDAQ under the ticker symbol "MBOT."

When did Microbot Medical's stock split? How did Microbot Medical's stock split work?

Microbot Medical's stock reverse split before market open on Monday, May 9th 2016. The 1-12 reverse split was announced on Friday, May 6th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 6th 2016. An investor that had 100 shares of Microbot Medical stock prior to the reverse split would have 8 shares after the split.

How were Microbot Medical's earnings last quarter?

Microbot Medical Inc (NASDAQ:MBOT) released its quarterly earnings data on Wednesday, November, 14th. The biotechnology company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($0.60) by $0.02. View Microbot Medical's Earnings History.

When is Microbot Medical's next earnings date?

Microbot Medical is scheduled to release their next quarterly earnings announcement on Wednesday, November 20th 2019. View Earnings Estimates for Microbot Medical.

What price target have analysts set for MBOT?

2 brokerages have issued 12 month price targets for Microbot Medical's stock. Their forecasts range from $1.75 to $10.00. On average, they anticipate Microbot Medical's stock price to reach $5.88 in the next year. This suggests a possible upside of 22.4% from the stock's current price. View Analyst Price Targets for Microbot Medical.

What is the consensus analysts' recommendation for Microbot Medical?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Microbot Medical in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Microbot Medical.

What are Wall Street analysts saying about Microbot Medical stock?

Here are some recent quotes from research analysts about Microbot Medical stock:
  • 1. According to Zacks Investment Research, "Microbot Medical Inc. is engaged in the research, design, development and commercialization of micro-robotics assisted medical technologies. Its product candidate includes the Self Cleaning Shunt for the treatment of hydrocephalus and Normal Pressure Hydrocephalus and TipCAT, a self-propelling, semi-disposable endoscope which is being developed initially for use in colonoscopy procedures. Microbot Medical Inc., formerly known as Stemcells, Inc., is headquartered in Hingham, MA. " (11/16/2019)
  • 2. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $60M, which includes a discounted cash flow (DCF)-based asset value of SCS, assuming 60% probability of approval, 20% discount rate and 2% terminal growth rate." (9/11/2019)

Has Microbot Medical been receiving favorable news coverage?

Media stories about MBOT stock have trended very negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Microbot Medical earned a daily sentiment score of -3.9 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Microbot Medical.

Are investors shorting Microbot Medical?

Microbot Medical saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 73,500 shares, a drop of 7.0% from the September 30th total of 79,000 shares. Based on an average trading volume of 89,800 shares, the days-to-cover ratio is presently 0.8 days. Approximately 2.9% of the company's shares are short sold. View Microbot Medical's Current Options Chain.

Who are some of Microbot Medical's key competitors?

What other stocks do shareholders of Microbot Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Microbot Medical investors own include TransEnterix (TRXC), Athersys (ATHX), Advanced Micro Devices (AMD), Novavax (NVAX), Alibaba Group (BABA), NovaBay Pharmaceuticals (NBY), General Electric (GE), Gilead Sciences (GILD), NVIDIA (NVDA) and Rigel Pharmaceuticals (RIGL).

Who are Microbot Medical's key executives?

Microbot Medical's management team includes the folowing people:
  • Mr. Harel Gadot, Co-Founder, Pres, CEO & Chairman (Age 46)
  • Mr. David Ben Naim CPA, M.B.A., Chief Financial Officer (Age 50)
  • Dr. Simon Sharon, CTO & Chairman of Scientific Advisory Board
  • Prof. Moshe Shoham, Co-Founder, Scientific Director & Member of Scientific Advisory Board (Age 67)
  • Dr. Eric C. Leuthardt, Scientific Director & Member of Scientific Advisory Board

How do I buy shares of Microbot Medical?

Shares of MBOT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Microbot Medical's stock price today?

One share of MBOT stock can currently be purchased for approximately $4.80.

How big of a company is Microbot Medical?

Microbot Medical has a market capitalization of $20.69 million. The biotechnology company earns $-7,240,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Microbot Medical employs 9 workers across the globe.View Additional Information About Microbot Medical.

What is Microbot Medical's official website?

The official website for Microbot Medical is http://www.microbotmedical.com/.

How can I contact Microbot Medical?

Microbot Medical's mailing address is 25 RECREATION PARK DRIVE UNIT 108, HINGHAM MA, 02043. The biotechnology company can be reached via phone at 781-875-3605 or via email at [email protected]


MarketBeat Community Rating for Microbot Medical (NASDAQ MBOT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  297 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  522
MarketBeat's community ratings are surveys of what our community members think about Microbot Medical and other stocks. Vote "Outperform" if you believe MBOT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBOT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel